Home / Resources / 6 Essential Strategies for Small Biotechs to Thrive in a Challenging Market

6 Essential Strategies for Small Biotechs to Thrive in a Challenging Market

Infographic
Clinical
6 Essential Strategies for Small Biotechs to Thrive cover

Small biotechs may be under pressure, but they’re also uniquely positioned to innovate, adapt, and lead.

Yet, amid these headwinds, there are also powerful tailwinds — emerging technologies, global trial opportunities, and a renewed focus on innovation — that can help small biotechs not only survive but thrive.

Download the infographic to learn more.


Related products
Consultant working on documents related to clinical strategy and planning with his laptop open in front of him
Consulting Clinical Strategy & Planning
Mitigate the risk of enrolment delays and plan your trials with confidence.
Citeline consulting expert providing actionable insights on feasibility activities.
Feasibility as a Service (FaaS)
Tap into our team of dedicated experts and expedite protocol, country and site feasibility activities
Citeline subscriber exploring the diversity feasibility using Global Patient Insights.
Global Patient Insights
Enabling sponsors to optimize investigator selection and hit diversity goals faster

Related resources

The Growing Pains of Chinese Biotech
NOV 08, 2023
Article
Commercial

The Growing Pains of Chinese Biotech

China’s emergence from API manufacturer to innovator, fueled by domestic funding and talent, has been one of the most notable trends of the last decade.

Disclosure as a Service Case Study resource card thumbnail
DEC 01, 2019
Case Study
Regulatory & Compliance

Small But Growing Biotech Manages Disclosure, Maintains Compliance, & Keeps Its Promise to Patients

While most large study sponsors place a high priority on transparency, smaller sponsors are not as quick to jump on the bandwagon. This one’s an exception.

Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial
Use Case
Patient Engagement & Recruitment

Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial

A biotech need to rapidly meet diversity/inclusion goals for a high-profile Phase III COVID-19 trial. Citeline Connect helped the sponsor recover from a 72% decline in diversity-focused randomizations, delivering 20-25% of daily randomizations in 32 days.

VIEW ALL